| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Activation of Double-Stranded RNA–Activated Protein Kinase in the Dorsal Root Ganglia and Spinal Dorsal Horn Regulates Neuropathic Pain Following Peripheral Nerve Injury in Rats
|
Zhang, Jian
|
|
|
19 |
4 |
p. 1381-1400
|
article
|
| 2 |
Activation of Double-Stranded RNA–Activated Protein Kinase in the Dorsal Root Ganglia and Spinal Dorsal Horn Regulates Neuropathic Pain Following Peripheral Nerve Injury in Rats
|
Zhang, Jian
|
|
|
19 |
4 |
p. 1381-1400
|
article
|
| 3 |
Altered Bioenergetics and Metabolic Homeostasis in Amyotrophic Lateral Sclerosis
|
Nelson, Andrew T.
|
|
|
19 |
4 |
p. 1102-1118
|
article
|
| 4 |
Altered Bioenergetics and Metabolic Homeostasis in Amyotrophic Lateral Sclerosis
|
Nelson, Andrew T.
|
|
|
19 |
4 |
p. 1102-1118
|
article
|
| 5 |
Antisense Oligonucleotides for the Study and Treatment of ALS
|
Boros, Benjamin D.
|
|
|
19 |
4 |
p. 1145-1158
|
article
|
| 6 |
Antisense Oligonucleotides for the Study and Treatment of ALS
|
Boros, Benjamin D.
|
|
|
19 |
4 |
p. 1145-1158
|
article
|
| 7 |
Approaches to Gene Modulation Therapy for ALS
|
Meijboom, Katharina E.
|
|
|
19 |
4 |
p. 1159-1179
|
article
|
| 8 |
Approaches to Gene Modulation Therapy for ALS
|
Meijboom, Katharina E.
|
|
|
19 |
4 |
p. 1159-1179
|
article
|
| 9 |
ASENT 2022 Annual Meeting
|
|
|
|
19 |
4 |
p. 1414-1431
|
article
|
| 10 |
Axon Biology in ALS: Mechanisms of Axon Degeneration and Prospects for Therapy
|
Coleman, Michael P.
|
|
|
19 |
4 |
p. 1133-1144
|
article
|
| 11 |
Axon Biology in ALS: Mechanisms of Axon Degeneration and Prospects for Therapy
|
Coleman, Michael P.
|
|
|
19 |
4 |
p. 1133-1144
|
article
|
| 12 |
Cerebellar Transcranial Direct Current Stimulation in Spinocerebellar Ataxia Type 3: a Randomized, Double-Blind, Sham-Controlled Trial
|
Maas, Roderick P. P. W. M.
|
|
|
19 |
4 |
p. 1259-1272
|
article
|
| 13 |
Cerebellar Transcranial Direct Current Stimulation in Spinocerebellar Ataxia Type 3: a Randomized, Double-Blind, Sham-Controlled Trial
|
Maas, Roderick P.P.W.M.
|
|
|
19 |
4 |
p. 1259-1272
|
article
|
| 14 |
Clinical and Preclinical Evidence for M1 Muscarinic Acetylcholine Receptor Potentiation as a Therapeutic Approach for Rett Syndrome
|
Smith, Mackenzie
|
|
|
19 |
4 |
p. 1340-1352
|
article
|
| 15 |
Clinical and Preclinical Evidence for M1 Muscarinic Acetylcholine Receptor Potentiation as a Therapeutic Approach for Rett Syndrome
|
Smith, Mackenzie
|
|
|
19 |
4 |
p. 1340-1352
|
article
|
| 16 |
Considerations for Amyotrophic Lateral Sclerosis (ALS) Clinical Trial Design
|
Fournier, Christina N.
|
|
|
19 |
4 |
p. 1180-1192
|
article
|
| 17 |
Considerations for Amyotrophic Lateral Sclerosis (ALS) Clinical Trial Design
|
Fournier, Christina N.
|
|
|
19 |
4 |
p. 1180-1192
|
article
|
| 18 |
Correction to: A Brain-Penetrant Stearoyl-CoA Desaturase Inhibitor Reverses α-Synuclein Toxicity
|
Nuber, Silke
|
|
|
19 |
4 |
p. 1434
|
article
|
| 19 |
Correction to: A Brain-Penetrant Stearoyl-CoA Desaturase Inhibitor Reverses α-Synuclein Toxicity
|
Nuber, Silke
|
|
|
19 |
4 |
p. 1434
|
article
|
| 20 |
Correction to: Luminescent Human iPSC-Derived Neurospheroids Enable Modeling of Neurotoxicity After Oxygen–glucose Deprivation
|
Van Breedam, Elise
|
|
|
19 |
4 |
p. 1433
|
article
|
| 21 |
Correction to: Luminescent Human iPSC-Derived Neurospheroids Enable Modeling of Neurotoxicity After Oxygen–glucose Deprivation
|
Van Breedam, Elise
|
|
|
19 |
4 |
p. 1433
|
article
|
| 22 |
Correction to: Pharmacological Rescue With SR8278, A Circadian Nuclear Receptor REV-ERBα Antagonist As A Therapy for Mood Disorders In Parkinson’s Disease
|
Kim, Jeongah
|
|
|
19 |
4 |
p. 1432
|
article
|
| 23 |
Correction to: Pharmacological Rescue With SR8278, A Circadian Nuclear Receptor REV-ERBα Antagonist As A Therapy for Mood Disorders In Parkinson's Disease
|
Kim, Jeongah
|
|
|
19 |
4 |
p. 1432
|
article
|
| 24 |
Deep Brain Stimulation for Addictive Disorders—Where Are We Now?
|
Yuen, Jason
|
|
|
19 |
4 |
p. 1193-1215
|
article
|
| 25 |
Deep Brain Stimulation for Addictive Disorders—Where Are We Now?
|
Yuen, Jason
|
|
|
19 |
4 |
p. 1193-1215
|
article
|
| 26 |
Deep Brain Stimulation for Depression
|
Figee, Martijn
|
|
|
19 |
4 |
p. 1229-1245
|
article
|
| 27 |
Deep Brain Stimulation for Depression
|
Figee, Martijn
|
|
|
19 |
4 |
p. 1229-1245
|
article
|
| 28 |
Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study
|
Benatar, Michael
|
|
|
19 |
4 |
p. 1248-1258
|
article
|
| 29 |
Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study
|
Benatar, Michael
|
|
|
19 |
4 |
p. 1248-1258
|
article
|
| 30 |
Does Ocrelizumab Limit Multiple Sclerosis Progression? Current Evidence from Clinical, MRI, and Fluid Biomarkers
|
Margoni, Monica
|
|
|
19 |
4 |
p. 1216-1228
|
article
|
| 31 |
Does Ocrelizumab Limit Multiple Sclerosis Progression? Current Evidence from Clinical, MRI, and Fluid Biomarkers
|
Margoni, Monica
|
|
|
19 |
4 |
p. 1216-1228
|
article
|
| 32 |
Efficacy of Repetitive Trans-spinal Magnetic Stimulation for Patients with Parkinson's Disease: a Randomised Controlled Trial
|
Mitsui, Takao
|
|
|
19 |
4 |
p. 1273-1282
|
article
|
| 33 |
Efficacy of Repetitive Trans-spinal Magnetic Stimulation for Patients with Parkinson’s Disease: a Randomised Controlled Trial
|
Mitsui, Takao
|
|
|
19 |
4 |
p. 1273-1282
|
article
|
| 34 |
Emerging Therapies and Novel Targets for TDP-43 Proteinopathy in ALS/FTD
|
Hayes, Lindsey R.
|
|
|
19 |
4 |
p. 1061-1084
|
article
|
| 35 |
Emerging Therapies and Novel Targets for TDP-43 Proteinopathy in ALS/FTD
|
Hayes, Lindsey R.
|
|
|
19 |
4 |
p. 1061-1084
|
article
|
| 36 |
ERRγ Ligand Regulates Adult Neurogenesis and Depression-like Behavior in a LRRK2-G2019S-associated Young Female Mouse Model of Parkinson's Disease
|
Kim, Hyo In
|
|
|
19 |
4 |
p. 1298-1312
|
article
|
| 37 |
ERRγ Ligand Regulates Adult Neurogenesis and Depression-like Behavior in a LRRK2-G2019S-associated Young Female Mouse Model of Parkinson’s Disease
|
Kim, Hyo In
|
|
|
19 |
4 |
p. 1298-1312
|
article
|
| 38 |
Fluconazole Is Neuroprotective via Interactions with the IGF-1 Receptor
|
Toodle, Valerie
|
|
|
19 |
4 |
p. 1313-1328
|
article
|
| 39 |
Fluconazole Is Neuroprotective via Interactions with the IGF-1 Receptor
|
Toodle, Valerie
|
|
|
19 |
4 |
p. 1313-1328
|
article
|
| 40 |
Impact of Genetic Testing on Therapeutic Decision-Making in Childhood-Onset Epilepsies—a Study in a Tertiary Epilepsy Center
|
Bayat, Allan
|
|
|
19 |
4 |
p. 1353-1367
|
article
|
| 41 |
Impact of Genetic Testing on Therapeutic Decision-Making in Childhood-Onset Epilepsies—a Study in a Tertiary Epilepsy Center
|
Bayat, Allan
|
|
|
19 |
4 |
p. 1353-1367
|
article
|
| 42 |
Improving Gene Therapy for Angelman Syndrome with Secreted Human UBE3A
|
Nenninger, Austin W.
|
|
|
19 |
4 |
p. 1329-1339
|
article
|
| 43 |
Improving Gene Therapy for Angelman Syndrome with Secreted Human UBE3A
|
Nenninger, Austin W.
|
|
|
19 |
4 |
p. 1329-1339
|
article
|
| 44 |
Inhibitions and Down-Regulation of Motor Protein Eg5 Expression in Primary Sensory Neurons Reveal a Novel Therapeutic Target for Pathological Pain
|
Wei, Na
|
|
|
19 |
4 |
p. 1401-1413
|
article
|
| 45 |
Inhibitions and Down-Regulation of Motor Protein Eg5 Expression in Primary Sensory Neurons Reveal a Novel Therapeutic Target for Pathological Pain
|
Wei, Na
|
|
|
19 |
4 |
p. 1401-1413
|
article
|
| 46 |
[No title]
|
|
|
|
19 |
4 |
p. 1414-1431
|
article
|
| 47 |
Nuclear Pore Dysfunction in Neurodegeneration
|
Spead, Olivia
|
|
|
19 |
4 |
p. 1050-1060
|
article
|
| 48 |
Nuclear Pore Dysfunction in Neurodegeneration
|
Spead, Olivia
|
|
|
19 |
4 |
p. 1050-1060
|
article
|
| 49 |
Pathogenic Extracellular Vesicle (EV) Signaling in Amyotrophic Lateral Sclerosis (ALS)
|
Kim, Gloria
|
|
|
19 |
4 |
p. 1119-1132
|
article
|
| 50 |
Pathogenic Extracellular Vesicle (EV) Signaling in Amyotrophic Lateral Sclerosis (ALS)
|
Kim, Gloria
|
|
|
19 |
4 |
p. 1119-1132
|
article
|
| 51 |
Preventing Amyotrophic Lateral Sclerosis Before It Starts: When to Intervene?
|
Cudkowicz, Merit
|
|
|
19 |
4 |
p. 1246-1247
|
article
|
| 52 |
Preventing Amyotrophic Lateral Sclerosis Before It Starts: When to Intervene?
|
Cudkowicz, Merit
|
|
|
19 |
4 |
p. 1246-1247
|
article
|
| 53 |
Pulsed-Focused Ultrasound Provides Long-Term Suppression of Epileptiform Bursts in the Kainic Acid-Induced Epilepsy Rat Model
|
Chu, Po-Chun
|
|
|
19 |
4 |
p. 1368-1380
|
article
|
| 54 |
Pulsed-Focused Ultrasound Provides Long-Term Suppression of Epileptiform Bursts in the Kainic Acid-Induced Epilepsy Rat Model
|
Chu, Po-Chun
|
|
|
19 |
4 |
p. 1368-1380
|
article
|
| 55 |
Retroviral Elements in Pathophysiology and as Therapeutic Targets for Amyotrophic Lateral Sclerosis
|
Li, Wenxue
|
|
|
19 |
4 |
p. 1085-1101
|
article
|
| 56 |
Retroviral Elements in Pathophysiology and as Therapeutic Targets for Amyotrophic Lateral Sclerosis
|
Li, Wenxue
|
|
|
19 |
4 |
p. 1085-1101
|
article
|
| 57 |
The Evolving Landscape of Motor Neuron Disease Therapeutics
|
Maragakis, Nicholas J.
|
|
|
19 |
4 |
p. 1047-1049
|
article
|
| 58 |
The Evolving Landscape of Motor Neuron Disease Therapeutics
|
Maragakis, Nicholas J.
|
|
|
19 |
4 |
p. 1047-1049
|
article
|
| 59 |
Treating Parkinson's Disease via Activation of BDNF/TrkB Signaling Pathways and Inhibition of Delta-Secretase
|
Kang, Seong Su
|
|
|
19 |
4 |
p. 1283-1297
|
article
|
| 60 |
Treating Parkinson’s Disease via Activation of BDNF/TrkB Signaling Pathways and Inhibition of Delta-Secretase
|
Kang, Seong Su
|
|
|
19 |
4 |
p. 1283-1297
|
article
|
Journal description